MILWAUKEE – October 29, 2026 -- The Society for Immunotherapy of Cancer (SITC) received almost 1,200 abstract submissions for 2026 and will showcase eight selected studies at a virtual press briefing on Wednesday, Nov. 4, from 12 to 1:30 p.m. MT.
SITC publishes accepted late-breaking abstracts ahead of its 41st Annual Meeting
The society has released titles and authors for the accepted Late-breaking Abstracts, which contain new data from interventional clinical trials in humans. They will be presented at the 41st Annual Meeting & Pre-Conference Programs, held Nov. 4-8, 2026, in Phoenix, AZ, and virtually.
Briefing lineup spans cell therapies, oncolytic viruses and a PD-1/VEGF bispecific
Eight presentations are scheduled, in this order:
- Abstract #553: Sanghyun Kim of the National Cancer Institute reports an interim phase II analysis of T cells engineered with mutant p53-specific TCRs in metastatic solid epithelial cancers.
- Abstract #323: Kevin Reynolds of Stanford Cancer Institute examines how anti-CAR immunity limits the durability of GD2-CAR T therapy in diffuse midline glioma.
- Abstract #566: Rodabe Amaria of MD Anderson presents pooled safety and updated efficacy data for OBX-115 TIL therapy in ICI-resistant advanced melanoma, using an IL2-free regimen.
- Abstract #1176: Patrick Grogan of Moffitt Cancer Center links adoptive immunotherapy after neoantigen vaccination to survival benefit in MGMT unmethylated glioblastoma multiforme.
- Abstract #828: Hong Jiang of MD Anderson shows oncolytic adenoviruses inducing tertiary lymphoid structures in brain tumors.
- Abstract #501: Ian Garbarine of The Ohio State University reports a phase 1b trial of intratumoral seasonal influenza vaccine in melanoma.
- Abstract #1182: Justin Moser of HonorHealth Research Institute presents a phase 1/1b study of the IL-2 prodrug WTX-124, alone or with pembrolizumab, in immunotherapy-sensitive solid tumors.
- Abstract #1185: Kai He of the University of Texas Mays Cancer Center presents phase 1/2 results for cesalatamig, a PD-1/VEGF bispecific antibody, in PD-(L)1-resistant or refractory NSCLC.
Press access requires registration, and some data may be embargoed
Journalists must register as press for SITC 2026 to attend. Each presentation will be followed by up to three minutes of media questions. Some briefing data may be embargoed to a later time during the meeting, and presenters will flag any such restrictions.